STADA’s growth journey continues in 2024

7 March 2025

German generics and consumer healthcare major STADA Arzneimittel (SAZ: Xetra) today released financial results, which the firm said continued its profitable growth journey in 2024 – supported by its strong commercial network in Europe, and complemented by a growing presence in the MENA, Eurasia and Asia-Pacific regions.

Group sales grew by 9% to 4.059 billion euros ($4.39 billion) versus the 2023 financial year. At the same time, earnings before interest, taxes, depreciation and amortization, adjusted for special items and currency effects, (adj cc EBITDA) rose by 11% to 886 million, while the adj cc EBITDA margin increased further to 21.8%.

STADA’s chief executive, Peter Goldschmidt, said: "We have again in 2024 demonstrated our ability to continue growing faster than the market in all our business segments. This is based on our entrepreneurial culture, our broad range of brands, our reliable production network, and the high level of trust we enjoy among our partners and customers."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK